Correlation Between Mineralys Therapeutics, and Immunome

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Immunome at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Immunome into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mineralys Therapeutics, Common and Immunome, you can compare the effects of market volatilities on Mineralys Therapeutics, and Immunome and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Immunome. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Immunome.

Diversification Opportunities for Mineralys Therapeutics, and Immunome

-0.41
  Correlation Coefficient

Very good diversification

The 3 months correlation between Mineralys and Immunome is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Immunome in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immunome and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Immunome. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immunome has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Immunome go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Immunome

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 1.17 times more return on investment than Immunome. However, Mineralys Therapeutics, is 1.17 times more volatile than Immunome. It trades about -0.04 of its potential returns per unit of risk. Immunome is currently generating about -0.17 per unit of risk. If you would invest  1,360  in Mineralys Therapeutics, Common on August 25, 2024 and sell it today you would lose (111.00) from holding Mineralys Therapeutics, Common or give up 8.16% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Mineralys Therapeutics, Common  vs.  Immunome

 Performance 
       Timeline  
Mineralys Therapeutics, 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in December 2024.
Immunome 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Immunome has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Mineralys Therapeutics, and Immunome Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Mineralys Therapeutics, and Immunome

The main advantage of trading using opposite Mineralys Therapeutics, and Immunome positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Immunome can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunome will offset losses from the drop in Immunome's long position.
The idea behind Mineralys Therapeutics, Common and Immunome pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume